The Valley Desk

ReviewFuture oncology (London, England)Published

LITESPARK-012: pembrolizumab plus lenvatinib with or without belzutifan or quavonlimab for advanced renal cell carcinoma

Read the publication ↗ Open access copy ↗

Regional connection

Verified An author affiliation on the Europe PMC record names Fox Chase Cancer Center, with Temple Health linked by the institution reference. Affiliation source

Publication record

Type
Review
Venue
Future oncology (London, England)
Published
Subject terms
Humans; Carcinoma, Renal Cell; Kidney Neoplasms; Phenylurea Compounds; Quinolines; Indenes; Vascular Endothelial Growth Factor A; Antineoplastic Agents; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Clear Cell Renal Cell Carcinoma; Immune Checkpoint Inhibitor
PubMed ID
37882432
Open access
Yes, open
Added to directory
Source checked

Report a correction or request removal